JP Morgan Maintains Neutral on NovoCure, Raises Price Target to $99

Benzinga · 01/06/2023 16:07
JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $86 to $99.